Diagnostic techniques and prognostic indicators

Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Horger M et al. Eur Radiol. 2016 Nov 23. [Epub ahead of print]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Predictors of inferior clinical outcome in patients with…

Details

Related conditions

Plasma cell leukemia: update on biology and therapy. Mina R et al. Leuk Lymphoma. 2016 Nov 6:1-10. [Epub ahead of print]. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. Maciocia N et al. Hematol Oncol. 2016 Nov 2. doi: 10.1002/hon.2345. [Epub ahead of print]. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition…

Details

Emerging treatments

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma(MUK-six): a multicentre, open-label, phase 1/2 trial. Popat R et al. Lancet Haematol. 2016 Nov 11. pii: S2352-3026(16)30165-X. doi: 10.1016/S2352-3026(16)30165-X. [Epub ahead of print]. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens. Sanchez L et al. Br J Haematol. 2016…

Details

Biology and genetics

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Li N et al. Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma. Jiménez C et al. J Mol Diagn. 2016 Nov 15. pii: S1525-1578(16)30186-6. doi: 10.1016/j.jmoldx.2016.08.004. [Epub ahead of print]. Exome copy number variation detection:…

Details

General

Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Malard F et al. Cancer Treat Rev. 2016 Nov 15;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. [Epub ahead of print]. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Musto P et al. Ann Oncol. 2016 Nov 17. pii: mdw606. [Epub ahead of print]. Aging, ‘Treating the Older Patient’. Rosko A et al. Biol…

Details

Supportive care

Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Isoda A et al. Int J Hematol. 2016 Nov 21. [Epub ahead of print]. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Kurtz JE et al. Onco Targets Ther. 2016 Oct 28;9:6689-6693. eCollection 2016. Percutaneous sacroplasty…

Details

Complications of myeloma and its treatments

Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractorymultiple myeloma patients. Kotchetkov R et al. Cancer Med. 2016 Nov 18. doi: 10.1002/cam4.799. [Epub ahead of print]. Safety of proteasome inhibitors for treatment of multiple myeloma. Schlafer D et al. Expert Opin Drug Saf. 2016 Nov 14. [Epub ahead of print]. Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors. Jouni H et al. Am J…

Details

Current treatments

Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Spoerl S et al. Transfusion. 2016 Nov 18. doi: 10.1111/trf.13883. [Epub ahead of print]. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Cornell RF et al. Biol Blood Marrow Transplant. 2016 Nov 15. pii: S1083-8791(16)30489-X. doi: 10.1016/j.bbmt.2016.11.011. [Epub ahead of print]. Absence…

Details

EU grants marketing approval for Ninlaro®

Takeda Pharmaceutical Company Ltd has announced that the European Commission has granted conditional marketing authorisation for Ninlaro (ixazomib) as a treatment in combination with Revlimid® and dexamethasone for relapsed and/or refractory myeloma patients who have received at least one previous line of treatment. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Details